Radiation Epidemiology Branch, National Cancer Institute, Bethesda, MD 20892, USA.
Lancet Oncol. 2011 Apr;12(4):353-60. doi: 10.1016/S1470-2045(11)70061-4.
Improvements in cancer survival have made the long-term risks from treatments more important, including the risk of developing a second cancer after radiotherapy. We aimed to estimate the proportion of second cancers attributable to radiotherapy in adults with data from the US Surveillance, Epidemiology and End Results (SEER) cancer registries.
We used nine of the SEER registries to systematically analyse 15 cancer sites that are routinely treated with radiotherapy (oral and pharynx, salivary gland, rectum, anus, larynx, lung, soft tissue, female breast, cervix, endometrial, prostate, testes, eye and orbit, brain and CNS, and thyroid). The cohort we studied was composed of patients aged 20 years or older who were diagnosed with a first primary invasive solid cancer reported in the SEER registries between Jan 1, 1973, and Dec 31, 2002. Relative risks (RRs) for second cancer in patients treated with radiotherapy versus patients not treated with radiotherapy were estimated with Poisson regression adjusted for age, stage, and other potential confounders.
647,672 cancer patients who were 5-year survivors were followed up for a mean 12 years (SD 4.5, range 5-34); 60,271 (9%) developed a second solid cancer. For each of the first cancer sites the RR of developing a second cancer associated with radiotherapy exceeded 1, and varied from 1.08 (95% CI 0.79-1.46) after cancers of the eye and orbit to 1.43 (1.13-1.84) after cancer of the testes. In general, the RR was highest for organs that typically received greater than 5 Gy, decreased with increasing age at diagnosis, and increased with time since diagnosis. We estimated a total of 3266 (2862-3670) excess second solid cancers that could be related to radiotherapy, that is 8% (7-9) of the total in all radiotherapy patients (≥1 year survivors) and five excess cancers per 1000 patients treated with radiotherapy by 15 years after diagnosis.
A relatively small proportion of second cancers are related to radiotherapy in adults, suggesting that most are due to other factors, such as lifestyle or genetics.
US National Cancer Institute.
癌症存活率的提高使得治疗的长期风险变得更加重要,包括放疗后发生第二癌症的风险。我们旨在利用美国监测、流行病学和最终结果(SEER)癌症登记处的数据,估计第二癌症归因于放疗的比例,这些第二癌症发生在接受放疗治疗的成年人中。
我们使用九个 SEER 登记处,系统地分析了 15 个常规接受放疗治疗的癌症部位(口腔和咽部、唾液腺、直肠、肛门、喉、肺、软组织、女性乳房、子宫颈、子宫内膜、前列腺、睾丸、眼睛和眼眶、脑和中枢神经系统、甲状腺)。我们研究的队列由年龄在 20 岁或以上的患者组成,这些患者在 1973 年 1 月 1 日至 2002 年 12 月 31 日期间被诊断为第一原发性浸润性实体癌,并在 SEER 登记处报告。用泊松回归法估计接受放疗与未接受放疗的患者发生第二癌症的相对风险(RR),并调整年龄、分期和其他潜在混杂因素。
647672 名癌症患者在 5 年生存后平均随访 12 年(标准差 4.5,范围 5-34);60271 名(9%)患者发生了第二实体癌。对于每个第一癌症部位,与放疗相关的第二癌症发生 RR 均大于 1,从眼部和眼眶癌症的 1.08(95%CI 0.79-1.46)到睾丸癌症的 1.43(1.13-1.84)不等。一般来说,RR 对于通常接受大于 5Gy 的器官最高,随着诊断时年龄的增加而降低,并且随着诊断后时间的增加而增加。我们估计总共 3266(2862-3670)例可归因于放疗的额外第二实体癌,即所有接受放疗的患者(≥1 年生存者)总数的 8%(7-9),以及每 1000 例接受放疗的患者中 15 年后每例发生 5 例额外癌症。
成年人中相对较小比例的第二癌症与放疗有关,这表明大多数是由于其他因素,如生活方式或遗传因素。
美国国家癌症研究所。